 Tyler Robin
Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 12 | 2023 | 299 | 3.650 |
Why?
| | Small Cell Lung Carcinoma | 6 | 2023 | 77 | 2.790 |
Why?
| | Brain Neoplasms | 10 | 2023 | 979 | 2.260 |
Why?
| | Lung Neoplasms | 10 | 2023 | 2177 | 1.720 |
Why?
| | Uterine Cervical Neoplasms | 7 | 2023 | 216 | 1.620 |
Why?
| | Brachytherapy | 8 | 2023 | 103 | 1.600 |
Why?
| | Cranial Irradiation | 4 | 2020 | 66 | 1.460 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 6 | 2023 | 961 | 1.160 |
Why?
| | Prostatic Neoplasms | 4 | 2023 | 921 | 1.100 |
Why?
| | Prostate-Specific Antigen | 2 | 2021 | 151 | 0.860 |
Why?
| | Radiotherapy, Adjuvant | 4 | 2019 | 182 | 0.790 |
Why?
| | Melanoma | 2 | 2018 | 620 | 0.750 |
Why?
| | Standard of Care | 2 | 2021 | 62 | 0.690 |
Why?
| | Oropharyngeal Neoplasms | 2 | 2016 | 38 | 0.610 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2018 | 124 | 0.600 |
Why?
| | CTLA-4 Antigen | 1 | 2018 | 76 | 0.600 |
Why?
| | Prostatectomy | 1 | 2018 | 98 | 0.590 |
Why?
| | Radiation Oncology | 1 | 2018 | 75 | 0.580 |
Why?
| | Oncologists | 1 | 2018 | 31 | 0.580 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2017 | 9 | 0.570 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2017 | 15 | 0.560 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2017 | 17 | 0.560 |
Why?
| | Chemoradiotherapy | 3 | 2019 | 188 | 0.560 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2017 | 17 | 0.560 |
Why?
| | Nose Neoplasms | 1 | 2017 | 15 | 0.560 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 194 | 0.540 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2016 | 29 | 0.530 |
Why?
| | Antibodies | 1 | 2018 | 371 | 0.520 |
Why?
| | Physician's Role | 1 | 2018 | 197 | 0.520 |
Why?
| | Submandibular Gland | 1 | 2015 | 15 | 0.500 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 268 | 0.500 |
Why?
| | Adenocarcinoma | 2 | 2021 | 795 | 0.490 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2017 | 577 | 0.480 |
Why?
| | Protein Tyrosine Phosphatases | 2 | 2014 | 147 | 0.480 |
Why?
| | Aged | 18 | 2021 | 19074 | 0.480 |
Why?
| | Liver Neoplasms | 1 | 2018 | 506 | 0.470 |
Why?
| | Internet | 1 | 2018 | 596 | 0.450 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 462 | 0.440 |
Why?
| | Head and Neck Neoplasms | 1 | 2017 | 427 | 0.410 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2012 | 17 | 0.410 |
Why?
| | RNA-Binding Protein EWS | 1 | 2012 | 17 | 0.400 |
Why?
| | Radiotherapy Dosage | 5 | 2023 | 244 | 0.400 |
Why?
| | Humans | 43 | 2023 | 114689 | 0.400 |
Why?
| | Databases, Factual | 6 | 2021 | 1125 | 0.400 |
Why?
| | Neoadjuvant Therapy | 4 | 2018 | 304 | 0.400 |
Why?
| | Genital Neoplasms, Female | 2 | 2023 | 70 | 0.390 |
Why?
| | Pancreatic Neoplasms | 2 | 2017 | 731 | 0.390 |
Why?
| | Neoplasm Staging | 7 | 2021 | 1167 | 0.380 |
Why?
| | Sarcoma, Ewing | 1 | 2012 | 64 | 0.380 |
Why?
| | Healthcare Disparities | 1 | 2016 | 480 | 0.370 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2012 | 179 | 0.350 |
Why?
| | Bone Neoplasms | 1 | 2012 | 194 | 0.340 |
Why?
| | Female | 26 | 2023 | 59511 | 0.330 |
Why?
| | Combined Modality Therapy | 5 | 2019 | 1121 | 0.330 |
Why?
| | Neoplasms | 2 | 2020 | 2097 | 0.320 |
Why?
| | Middle Aged | 17 | 2021 | 26737 | 0.320 |
Why?
| | Endometrial Neoplasms | 2 | 2021 | 141 | 0.310 |
Why?
| | Margins of Excision | 2 | 2019 | 29 | 0.300 |
Why?
| | Hysterectomy | 2 | 2019 | 106 | 0.300 |
Why?
| | Aged, 80 and over | 7 | 2021 | 6347 | 0.290 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2017 | 40 | 0.280 |
Why?
| | Retrospective Studies | 10 | 2023 | 12551 | 0.280 |
Why?
| | Lymph Nodes | 2 | 2021 | 419 | 0.280 |
Why?
| | Male | 15 | 2023 | 55599 | 0.270 |
Why?
| | Treatment Outcome | 7 | 2022 | 9088 | 0.270 |
Why?
| | MicroRNAs | 1 | 2012 | 600 | 0.260 |
Why?
| | Survival Analysis | 3 | 2018 | 1211 | 0.250 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2019 | 1141 | 0.250 |
Why?
| | Neoplasm Metastasis | 3 | 2017 | 523 | 0.250 |
Why?
| | DNA-Binding Proteins | 1 | 2012 | 1314 | 0.250 |
Why?
| | Fiducial Markers | 1 | 2023 | 8 | 0.220 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 40 | 0.210 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 2 | 2022 | 117 | 0.200 |
Why?
| | Prognosis | 3 | 2018 | 3329 | 0.190 |
Why?
| | Follow-Up Studies | 4 | 2018 | 4411 | 0.190 |
Why?
| | Adult | 12 | 2021 | 30550 | 0.190 |
Why?
| | Breast Neoplasms | 4 | 2019 | 1862 | 0.190 |
Why?
| | Lymphatic Metastasis | 1 | 2021 | 275 | 0.180 |
Why?
| | Simulation Training | 1 | 2021 | 61 | 0.180 |
Why?
| | Young Adult | 7 | 2021 | 10470 | 0.170 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2018 | 332 | 0.160 |
Why?
| | Survival Rate | 3 | 2019 | 1644 | 0.160 |
Why?
| | Aquaporin 4 | 1 | 2019 | 87 | 0.160 |
Why?
| | Carcinosarcoma | 1 | 2018 | 17 | 0.150 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 30 | 0.150 |
Why?
| | Radiometry | 1 | 2018 | 42 | 0.150 |
Why?
| | Necrosis | 1 | 2019 | 211 | 0.150 |
Why?
| | Machine Learning | 1 | 2021 | 316 | 0.150 |
Why?
| | India | 1 | 2018 | 134 | 0.150 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2018 | 34 | 0.150 |
Why?
| | Uterine Neoplasms | 1 | 2018 | 73 | 0.150 |
Why?
| | Biopsy | 1 | 2021 | 1036 | 0.150 |
Why?
| | Salvage Therapy | 1 | 2018 | 127 | 0.140 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 385 | 0.140 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 152 | 0.140 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2017 | 33 | 0.140 |
Why?
| | Thymus Neoplasms | 1 | 2017 | 21 | 0.140 |
Why?
| | Thymoma | 1 | 2017 | 30 | 0.140 |
Why?
| | Radiotherapy, Conformal | 1 | 2017 | 68 | 0.140 |
Why?
| | Patient Preference | 1 | 2018 | 167 | 0.130 |
Why?
| | Database Management Systems | 1 | 2016 | 47 | 0.130 |
Why?
| | Alphapapillomavirus | 1 | 2016 | 36 | 0.130 |
Why?
| | Propensity Score | 1 | 2017 | 224 | 0.130 |
Why?
| | Forecasting | 1 | 2017 | 330 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2019 | 1214 | 0.130 |
Why?
| | Organs at Risk | 1 | 2015 | 30 | 0.120 |
Why?
| | Postoperative Care | 1 | 2017 | 222 | 0.120 |
Why?
| | Organ Sparing Treatments | 1 | 2015 | 31 | 0.120 |
Why?
| | Thyroid Neoplasms | 1 | 2018 | 264 | 0.120 |
Why?
| | Mass Screening | 1 | 2021 | 1004 | 0.120 |
Why?
| | Patient Selection | 1 | 2018 | 641 | 0.120 |
Why?
| | Disease Progression | 2 | 2018 | 2380 | 0.120 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 718 | 0.120 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2015 | 52 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 811 | 0.110 |
Why?
| | Radiation Injuries | 1 | 2015 | 128 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1075 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1430 | 0.110 |
Why?
| | Internship and Residency | 1 | 2021 | 926 | 0.100 |
Why?
| | Feasibility Studies | 1 | 2015 | 740 | 0.100 |
Why?
| | United States | 7 | 2023 | 12183 | 0.100 |
Why?
| | Genes, Tumor Suppressor | 1 | 2012 | 77 | 0.100 |
Why?
| | Etoposide | 1 | 2012 | 148 | 0.100 |
Why?
| | Colorectal Neoplasms | 1 | 2018 | 615 | 0.100 |
Why?
| | Cell Line, Tumor | 3 | 2018 | 2710 | 0.100 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2387 | 0.100 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2014 | 386 | 0.100 |
Why?
| | Doxorubicin | 1 | 2012 | 285 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1355 | 0.090 |
Why?
| | Adolescent | 6 | 2021 | 17848 | 0.090 |
Why?
| | Ovarian Neoplasms | 1 | 2015 | 388 | 0.090 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2011 | 167 | 0.090 |
Why?
| | Cell Movement | 1 | 2014 | 869 | 0.080 |
Why?
| | ErbB Receptors | 2 | 2023 | 554 | 0.080 |
Why?
| | Nuclear Proteins | 1 | 2014 | 591 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 448 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 347 | 0.080 |
Why?
| | Prospective Studies | 2 | 2023 | 6220 | 0.080 |
Why?
| | Cell Survival | 1 | 2012 | 1021 | 0.080 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 1879 | 0.080 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2012 | 636 | 0.070 |
Why?
| | Infant, Newborn | 2 | 2017 | 5047 | 0.070 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2006 | 153 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 4623 | 0.070 |
Why?
| | Infant | 2 | 2017 | 7963 | 0.060 |
Why?
| | Child, Preschool | 2 | 2017 | 9116 | 0.060 |
Why?
| | Cell Proliferation | 2 | 2012 | 2187 | 0.060 |
Why?
| | Child | 3 | 2021 | 18415 | 0.050 |
Why?
| | Androgen Antagonists | 1 | 2023 | 69 | 0.050 |
Why?
| | Hormones | 1 | 2023 | 132 | 0.050 |
Why?
| | Developing Countries | 1 | 2023 | 235 | 0.050 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2022 | 226 | 0.040 |
Why?
| | Yersinia Infections | 1 | 1979 | 4 | 0.040 |
Why?
| | Luminescence | 1 | 2018 | 33 | 0.040 |
Why?
| | Gene Rearrangement | 1 | 2018 | 135 | 0.040 |
Why?
| | Neoplasm Transplantation | 1 | 2018 | 228 | 0.040 |
Why?
| | SEER Program | 1 | 2018 | 196 | 0.040 |
Why?
| | Receptor, ErbB-2 | 1 | 2019 | 300 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 1796 | 0.030 |
Why?
| | Mice, Nude | 1 | 2018 | 630 | 0.030 |
Why?
| | Regression Analysis | 1 | 2019 | 945 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 2765 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 819 | 0.030 |
Why?
| | Liver | 1 | 2023 | 1637 | 0.030 |
Why?
| | Clinical Competence | 1 | 2021 | 893 | 0.030 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2014 | 73 | 0.030 |
Why?
| | Calorimetry | 1 | 2014 | 60 | 0.030 |
Why?
| | Allosteric Regulation | 1 | 2014 | 81 | 0.030 |
Why?
| | Molecular Docking Simulation | 1 | 2014 | 101 | 0.030 |
Why?
| | Magnesium | 1 | 2014 | 145 | 0.030 |
Why?
| | Risk Assessment | 1 | 2022 | 2968 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 1841 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2014 | 353 | 0.030 |
Why?
| | Crystallography, X-Ray | 1 | 2014 | 402 | 0.030 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2014 | 238 | 0.030 |
Why?
| | Cohort Studies | 1 | 2021 | 4895 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1518 | 0.020 |
Why?
| | Brain | 1 | 2022 | 2371 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2012 | 168 | 0.020 |
Why?
| | Registries | 1 | 2018 | 1768 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 750 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1177 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2014 | 1982 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2014 | 2785 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2018 | 3535 | 0.020 |
Why?
| | Protein Binding | 1 | 2014 | 1890 | 0.020 |
Why?
| | Cell Line | 1 | 2014 | 2637 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2011 | 329 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3053 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 932 | 0.020 |
Why?
| | Cyclin B1 | 1 | 2006 | 5 | 0.020 |
Why?
| | Cyclin B | 1 | 2006 | 13 | 0.020 |
Why?
| | Cyclin A | 1 | 2006 | 15 | 0.020 |
Why?
| | Maleimides | 1 | 2006 | 24 | 0.020 |
Why?
| | Cyclin E | 1 | 2006 | 21 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2012 | 951 | 0.020 |
Why?
| | G2 Phase | 1 | 2006 | 31 | 0.020 |
Why?
| | Flavonoids | 1 | 2006 | 66 | 0.020 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2006 | 68 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 107 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 146 | 0.020 |
Why?
| | Risk Factors | 1 | 2019 | 8632 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 164 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2006 | 273 | 0.010 |
Why?
| | Cell Division | 1 | 2006 | 758 | 0.010 |
Why?
| | Indoles | 1 | 2006 | 304 | 0.010 |
Why?
| | Animals | 2 | 2018 | 31706 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2363 | 0.010 |
Why?
| | Mice | 1 | 2018 | 14869 | 0.010 |
Why?
| | Phosphorylation | 1 | 2006 | 1569 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2006 | 785 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 4513 | 0.010 |
Why?
| | Yersinia | 1 | 1979 | 2 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2006 | 2553 | 0.010 |
Why?
| | Serotyping | 1 | 1979 | 28 | 0.010 |
Why?
| | New York City | 1 | 1979 | 70 | 0.010 |
Why?
| | Species Specificity | 1 | 1979 | 542 | 0.010 |
Why?
|
|
Robin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|